TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells
Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of s...
Gespeichert in:
| Veröffentlicht in: | Cancer letters 2013-07, Vol.335 (1), p.119-127 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 127 |
|---|---|
| container_issue | 1 |
| container_start_page | 119 |
| container_title | Cancer letters |
| container_volume | 335 |
| creator | Jähnisch, Hanka Wehner, Rebekka Tunger, Antje Kunze, Anja Oehrl, Stephanie Schäkel, Knut Rohayem, Jacques Bornhäuser, Martin Tonn, Torsten Bachmann, Michael Schmitz, Marc |
| description | Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of slanDCs to activate natural killer cells. ► Imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs. |
| doi_str_mv | 10.1016/j.canlet.2013.02.003 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1505344142</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0304383513001146</els_id><sourcerecordid>1505344142</sourcerecordid><originalsourceid>FETCH-LOGICAL-c502t-cf5b6eb9fa068badec24aa8e283a4fbfa560e211c68133c13f46da8fda71d27c3</originalsourceid><addsrcrecordid>eNqFks2L1EAQxRtR3HH1PxANePGSbPVX0nMRlsUvGBTc3ZvQdDrVY49JeuxOhPnv7ZBVYS97qsvvPV7VK0JeUqgo0PriUFkz9jhVDCivgFUA_BHZUNWwstkqeEw2wEGUXHF5Rp6ldAAAKRr5lJwxLoApSjfk-83uW3OhCrMPo09TKqbo93uMhR-GeQxp8sPcmynEU3GM4Yhx8piK4Iof82DGoi7T3LtQ7Iz9cmmLDscu-snbwmLfp-fkiTN9whd385zcfnh_c_Wp3H39-PnqcldaCWwqrZNtje3WGahVazq0TBijkCluhGudkTUgo9TWinJuKXei7oxynWloxxrLz8nb1TdH_DVjmvTg05LAjBjmpKkEyYWggj2McllzpSTfZvTNPfQQ5jjmRTSthcxX37ImU2KlbAwpRXT6GP1g4klT0EtR-qDXovRSlAamc1FZ9urOfG4H7P6J_jaTgdcr4EzQZh990rfX2UHCIs81ZuLdSmA-7W-PUSfrcbTY-Yh20l3wD2W4b2B7P3pr-p94wvR_W52yQF8v77R8E-UAlIqa_wEl-sNg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1645013927</pqid></control><display><type>article</type><title>TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells</title><source>MEDLINE</source><source>ScienceDirect Journals (5 years ago - present)</source><creator>Jähnisch, Hanka ; Wehner, Rebekka ; Tunger, Antje ; Kunze, Anja ; Oehrl, Stephanie ; Schäkel, Knut ; Rohayem, Jacques ; Bornhäuser, Martin ; Tonn, Torsten ; Bachmann, Michael ; Schmitz, Marc</creator><creatorcontrib>Jähnisch, Hanka ; Wehner, Rebekka ; Tunger, Antje ; Kunze, Anja ; Oehrl, Stephanie ; Schäkel, Knut ; Rohayem, Jacques ; Bornhäuser, Martin ; Tonn, Torsten ; Bachmann, Michael ; Schmitz, Marc</creatorcontrib><description>Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of slanDCs to activate natural killer cells. ► Imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs.</description><identifier>ISSN: 0304-3835</identifier><identifier>EISSN: 1872-7980</identifier><identifier>DOI: 10.1016/j.canlet.2013.02.003</identifier><identifier>PMID: 23402811</identifier><language>eng</language><publisher>Ireland: Elsevier Ireland Ltd</publisher><subject>agonists ; Aminoquinolines - pharmacology ; Antigens ; Antigens, CD - metabolism ; Antineoplastic Agents - pharmacology ; Apoptosis ; B7-2 Antigen - metabolism ; Biological activity ; Cancer ; CD83 Antigen ; Cell Proliferation ; Coculture Techniques ; Cytokines ; Cytokines - metabolism ; Cytotoxicity ; Cytotoxicity, Immunologic - drug effects ; Dendritic cells ; Dendritic Cells - drug effects ; Dendritic Cells - immunology ; Dendritic Cells - metabolism ; Drug Screening Assays, Antitumor ; Hematology, Oncology and Palliative Medicine ; HLA-DR Antigens - metabolism ; HT29 Cells ; Humans ; Imidazoles - pharmacology ; Imiquimod ; Immune system ; Immunoglobulins - metabolism ; Immunomodulation - drug effects ; Immunotherapy ; Inflammation Mediators - metabolism ; K562 Cells ; Killer Cells, Natural - immunology ; Lymphocyte Activation ; Lymphocytes ; Melanoma ; Membrane Glycoproteins - metabolism ; natural killer cells ; Resiquimod ; Rodents ; Studies ; T-lymphocytes ; T-Lymphocytes - immunology ; therapeutics ; Toll-Like Receptor 7 - agonists ; Toll-Like Receptor 7 - metabolism ; Toll-Like Receptor 8 - agonists ; Toll-Like Receptor 8 - metabolism ; Tumor immunology</subject><ispartof>Cancer letters, 2013-07, Vol.335 (1), p.119-127</ispartof><rights>2013</rights><rights>Copyright © 2013. Published by Elsevier Ireland Ltd.</rights><rights>Copyright Elsevier Limited Jul 10, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c502t-cf5b6eb9fa068badec24aa8e283a4fbfa560e211c68133c13f46da8fda71d27c3</citedby><cites>FETCH-LOGICAL-c502t-cf5b6eb9fa068badec24aa8e283a4fbfa560e211c68133c13f46da8fda71d27c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0304383513001146$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23402811$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jähnisch, Hanka</creatorcontrib><creatorcontrib>Wehner, Rebekka</creatorcontrib><creatorcontrib>Tunger, Antje</creatorcontrib><creatorcontrib>Kunze, Anja</creatorcontrib><creatorcontrib>Oehrl, Stephanie</creatorcontrib><creatorcontrib>Schäkel, Knut</creatorcontrib><creatorcontrib>Rohayem, Jacques</creatorcontrib><creatorcontrib>Bornhäuser, Martin</creatorcontrib><creatorcontrib>Tonn, Torsten</creatorcontrib><creatorcontrib>Bachmann, Michael</creatorcontrib><creatorcontrib>Schmitz, Marc</creatorcontrib><title>TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells</title><title>Cancer letters</title><addtitle>Cancer Lett</addtitle><description>Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of slanDCs to activate natural killer cells. ► Imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs.</description><subject>agonists</subject><subject>Aminoquinolines - pharmacology</subject><subject>Antigens</subject><subject>Antigens, CD - metabolism</subject><subject>Antineoplastic Agents - pharmacology</subject><subject>Apoptosis</subject><subject>B7-2 Antigen - metabolism</subject><subject>Biological activity</subject><subject>Cancer</subject><subject>CD83 Antigen</subject><subject>Cell Proliferation</subject><subject>Coculture Techniques</subject><subject>Cytokines</subject><subject>Cytokines - metabolism</subject><subject>Cytotoxicity</subject><subject>Cytotoxicity, Immunologic - drug effects</subject><subject>Dendritic cells</subject><subject>Dendritic Cells - drug effects</subject><subject>Dendritic Cells - immunology</subject><subject>Dendritic Cells - metabolism</subject><subject>Drug Screening Assays, Antitumor</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>HLA-DR Antigens - metabolism</subject><subject>HT29 Cells</subject><subject>Humans</subject><subject>Imidazoles - pharmacology</subject><subject>Imiquimod</subject><subject>Immune system</subject><subject>Immunoglobulins - metabolism</subject><subject>Immunomodulation - drug effects</subject><subject>Immunotherapy</subject><subject>Inflammation Mediators - metabolism</subject><subject>K562 Cells</subject><subject>Killer Cells, Natural - immunology</subject><subject>Lymphocyte Activation</subject><subject>Lymphocytes</subject><subject>Melanoma</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>natural killer cells</subject><subject>Resiquimod</subject><subject>Rodents</subject><subject>Studies</subject><subject>T-lymphocytes</subject><subject>T-Lymphocytes - immunology</subject><subject>therapeutics</subject><subject>Toll-Like Receptor 7 - agonists</subject><subject>Toll-Like Receptor 7 - metabolism</subject><subject>Toll-Like Receptor 8 - agonists</subject><subject>Toll-Like Receptor 8 - metabolism</subject><subject>Tumor immunology</subject><issn>0304-3835</issn><issn>1872-7980</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFks2L1EAQxRtR3HH1PxANePGSbPVX0nMRlsUvGBTc3ZvQdDrVY49JeuxOhPnv7ZBVYS97qsvvPV7VK0JeUqgo0PriUFkz9jhVDCivgFUA_BHZUNWwstkqeEw2wEGUXHF5Rp6ldAAAKRr5lJwxLoApSjfk-83uW3OhCrMPo09TKqbo93uMhR-GeQxp8sPcmynEU3GM4Yhx8piK4Iof82DGoi7T3LtQ7Iz9cmmLDscu-snbwmLfp-fkiTN9whd385zcfnh_c_Wp3H39-PnqcldaCWwqrZNtje3WGahVazq0TBijkCluhGudkTUgo9TWinJuKXei7oxynWloxxrLz8nb1TdH_DVjmvTg05LAjBjmpKkEyYWggj2McllzpSTfZvTNPfQQ5jjmRTSthcxX37ImU2KlbAwpRXT6GP1g4klT0EtR-qDXovRSlAamc1FZ9urOfG4H7P6J_jaTgdcr4EzQZh990rfX2UHCIs81ZuLdSmA-7W-PUSfrcbTY-Yh20l3wD2W4b2B7P3pr-p94wvR_W52yQF8v77R8E-UAlIqa_wEl-sNg</recordid><startdate>20130710</startdate><enddate>20130710</enddate><creator>Jähnisch, Hanka</creator><creator>Wehner, Rebekka</creator><creator>Tunger, Antje</creator><creator>Kunze, Anja</creator><creator>Oehrl, Stephanie</creator><creator>Schäkel, Knut</creator><creator>Rohayem, Jacques</creator><creator>Bornhäuser, Martin</creator><creator>Tonn, Torsten</creator><creator>Bachmann, Michael</creator><creator>Schmitz, Marc</creator><general>Elsevier Ireland Ltd</general><general>Elsevier Limited</general><scope>FBQ</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><scope>7T5</scope></search><sort><creationdate>20130710</creationdate><title>TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells</title><author>Jähnisch, Hanka ; Wehner, Rebekka ; Tunger, Antje ; Kunze, Anja ; Oehrl, Stephanie ; Schäkel, Knut ; Rohayem, Jacques ; Bornhäuser, Martin ; Tonn, Torsten ; Bachmann, Michael ; Schmitz, Marc</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c502t-cf5b6eb9fa068badec24aa8e283a4fbfa560e211c68133c13f46da8fda71d27c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>agonists</topic><topic>Aminoquinolines - pharmacology</topic><topic>Antigens</topic><topic>Antigens, CD - metabolism</topic><topic>Antineoplastic Agents - pharmacology</topic><topic>Apoptosis</topic><topic>B7-2 Antigen - metabolism</topic><topic>Biological activity</topic><topic>Cancer</topic><topic>CD83 Antigen</topic><topic>Cell Proliferation</topic><topic>Coculture Techniques</topic><topic>Cytokines</topic><topic>Cytokines - metabolism</topic><topic>Cytotoxicity</topic><topic>Cytotoxicity, Immunologic - drug effects</topic><topic>Dendritic cells</topic><topic>Dendritic Cells - drug effects</topic><topic>Dendritic Cells - immunology</topic><topic>Dendritic Cells - metabolism</topic><topic>Drug Screening Assays, Antitumor</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>HLA-DR Antigens - metabolism</topic><topic>HT29 Cells</topic><topic>Humans</topic><topic>Imidazoles - pharmacology</topic><topic>Imiquimod</topic><topic>Immune system</topic><topic>Immunoglobulins - metabolism</topic><topic>Immunomodulation - drug effects</topic><topic>Immunotherapy</topic><topic>Inflammation Mediators - metabolism</topic><topic>K562 Cells</topic><topic>Killer Cells, Natural - immunology</topic><topic>Lymphocyte Activation</topic><topic>Lymphocytes</topic><topic>Melanoma</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>natural killer cells</topic><topic>Resiquimod</topic><topic>Rodents</topic><topic>Studies</topic><topic>T-lymphocytes</topic><topic>T-Lymphocytes - immunology</topic><topic>therapeutics</topic><topic>Toll-Like Receptor 7 - agonists</topic><topic>Toll-Like Receptor 7 - metabolism</topic><topic>Toll-Like Receptor 8 - agonists</topic><topic>Toll-Like Receptor 8 - metabolism</topic><topic>Tumor immunology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jähnisch, Hanka</creatorcontrib><creatorcontrib>Wehner, Rebekka</creatorcontrib><creatorcontrib>Tunger, Antje</creatorcontrib><creatorcontrib>Kunze, Anja</creatorcontrib><creatorcontrib>Oehrl, Stephanie</creatorcontrib><creatorcontrib>Schäkel, Knut</creatorcontrib><creatorcontrib>Rohayem, Jacques</creatorcontrib><creatorcontrib>Bornhäuser, Martin</creatorcontrib><creatorcontrib>Tonn, Torsten</creatorcontrib><creatorcontrib>Bachmann, Michael</creatorcontrib><creatorcontrib>Schmitz, Marc</creatorcontrib><collection>AGRIS</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><jtitle>Cancer letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jähnisch, Hanka</au><au>Wehner, Rebekka</au><au>Tunger, Antje</au><au>Kunze, Anja</au><au>Oehrl, Stephanie</au><au>Schäkel, Knut</au><au>Rohayem, Jacques</au><au>Bornhäuser, Martin</au><au>Tonn, Torsten</au><au>Bachmann, Michael</au><au>Schmitz, Marc</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells</atitle><jtitle>Cancer letters</jtitle><addtitle>Cancer Lett</addtitle><date>2013-07-10</date><risdate>2013</risdate><volume>335</volume><issue>1</issue><spage>119</spage><epage>127</epage><pages>119-127</pages><issn>0304-3835</issn><eissn>1872-7980</eissn><abstract>Highlights ► Imiquimod and resiquimod enhance the secretion of various proinflammatory cytokines by slanDCs. ► Imiquimod and resiquimod augment the tumor-directed cytotoxic activity of slanDCs. ► Resiquimod improves slanDC-mediated stimulation of T lymphocytes. ► Resiquimod enhances the ability of slanDCs to activate natural killer cells. ► Imiquimod and resiquimod trigger various immunostimulatory properties of slanDCs.</abstract><cop>Ireland</cop><pub>Elsevier Ireland Ltd</pub><pmid>23402811</pmid><doi>10.1016/j.canlet.2013.02.003</doi><tpages>9</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0304-3835 |
| ispartof | Cancer letters, 2013-07, Vol.335 (1), p.119-127 |
| issn | 0304-3835 1872-7980 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1505344142 |
| source | MEDLINE; ScienceDirect Journals (5 years ago - present) |
| subjects | agonists Aminoquinolines - pharmacology Antigens Antigens, CD - metabolism Antineoplastic Agents - pharmacology Apoptosis B7-2 Antigen - metabolism Biological activity Cancer CD83 Antigen Cell Proliferation Coculture Techniques Cytokines Cytokines - metabolism Cytotoxicity Cytotoxicity, Immunologic - drug effects Dendritic cells Dendritic Cells - drug effects Dendritic Cells - immunology Dendritic Cells - metabolism Drug Screening Assays, Antitumor Hematology, Oncology and Palliative Medicine HLA-DR Antigens - metabolism HT29 Cells Humans Imidazoles - pharmacology Imiquimod Immune system Immunoglobulins - metabolism Immunomodulation - drug effects Immunotherapy Inflammation Mediators - metabolism K562 Cells Killer Cells, Natural - immunology Lymphocyte Activation Lymphocytes Melanoma Membrane Glycoproteins - metabolism natural killer cells Resiquimod Rodents Studies T-lymphocytes T-Lymphocytes - immunology therapeutics Toll-Like Receptor 7 - agonists Toll-Like Receptor 7 - metabolism Toll-Like Receptor 8 - agonists Toll-Like Receptor 8 - metabolism Tumor immunology |
| title | TLR7/8 agonists trigger immunostimulatory properties of human 6-sulfo LacNAc dendritic cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T17%3A11%3A18IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=TLR7/8%20agonists%20trigger%20immunostimulatory%20properties%20of%20human%206-sulfo%20LacNAc%20dendritic%20cells&rft.jtitle=Cancer%20letters&rft.au=J%C3%A4hnisch,%20Hanka&rft.date=2013-07-10&rft.volume=335&rft.issue=1&rft.spage=119&rft.epage=127&rft.pages=119-127&rft.issn=0304-3835&rft.eissn=1872-7980&rft_id=info:doi/10.1016/j.canlet.2013.02.003&rft_dat=%3Cproquest_cross%3E1505344142%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1645013927&rft_id=info:pmid/23402811&rft_els_id=S0304383513001146&rfr_iscdi=true |